The DOI matches its Crossref record.
Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice
Open accessAbstract
Little observational data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing hepatitis B mother-to-child transmission (MTCT) in real-world settings. During the period of January 2009 to March 2011, we enrolled hepatitis B e antigen–positive mothers with HBV DNA >6 log 10 copies/mL in China. At gestation week 28, the mothers received LdT or LAM until postpartum week 4 or no treatment (NTx). The study endpoints were the safety of LdT/LAM use and MTCT rates. Of the 700 mothers enrolled, 648 (LdT/LAM/NTx = 252/51/345) completed the 52-week study with 661 infants (LdT/LAM/NTx = 257/52/352). On treatment, viral rebound occurred in 1.6% of mothers, all resulting from medication noncompliance. There was no genotypic mutation detected. At delivery, significantly lower HBV DNA levels were noted in mothers who received LdT or LAM versus NTx. Alanine aminotransferase flares were observed in 17.1% of treated mothers versus 6.3% of untreated mothers (P < 0.001). At birth, hepatitis B surface antigen (HBsAg) was detected in 20% and 24% of newborns in the treated and NTx groups, respectively. At week 52, an intention-to-treat analysis indicated 2.2% (95% confidence [CI]: 0.6-3.8) of HBsAg+ infants from the treated group versus 7.6% (95% CI: 4.9-10.3) in the NTx group (P = 0.001) and no difference of HBsAg+ rate between infants in the LdT and LAM groups (1.9% vs. 3.7%; P = 0.758). On-treatment analysis indicated 0% of HBsAg+ infants in the treated group versus 2.84% in the NTx group (P = 0.002). There were no differences for gestational age or infants' height, weight, Apgar scores, or birth defect rates between infants from the treated and untreated groups. Conclusions: LdT and LAM use in late pregnancy for highly viremic mothers was equally effective in reducing MTCT. The treatment was well tolerated with no safety concerns identified. (Hepatology 2014;60:468–476)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Yuen, M.-F., Chen, D.-S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., Peters, M. G., & Lai, C.-L. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.35 · Cited by 814
Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load
Pan, C. Q., Duan, Z., Dai, E., Zhang, S., Han, G., Wang, Y., Zhang, H., Zou, H., Zhu, B., Zhao, W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508660 · Cited by 573
Self-citationViral hepatitis and liver cancer
Ringehan, M., McKeating, J. A., & Protzer, U. (2017) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0274 · Cited by 410
Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets
Spearman, C. W., Afihene, M., Ally, R., Apica, B., Awuku, Y., Cunha, L., Dusheiko, G., Gogela, N., Kassianides, C., Kew, M., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30295-9 · Cited by 361
Metadata
- Authors
- Zhang, H., Pan, C. Q., Pang, Q., Tian, R., Yan, M., & Liu, X.
- Venue
- Hepatology
- Published
- 2014-08
- Volume
- 60
- Issue
- 2
- Pages
- 468-476
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2142974747
- Cited by
- 199
- References
- 0
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. https://app.cochat.ai/papers/10.1002/hep.27034
- The paper
- Zhang, H., Pan, C. Q., Pang, Q., Tian, R., Yan, M., & Liu, X. (2014). Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. https://doi.org/10.1002/hep.27034
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.